Objective
To investigate the effect of batroxobin on the blood-retinal barrier (BRB) and vascular endothelial growth factors (VEGF) in diabetic rats.
Methods
Sixty Sprague-Dawley rats were used to establish diabetic models by intraperitoneal injecting with streptozotocin (60 mg/kg), and were divided into 3 groups: diabetic group (n=20), batroxobin (40 mg/kg) group (n=20) and batroxobin (20 mg/kg) group (n=20). Twenty-five else rats were in control group. All of the rats were executed 7 days later. The function of BRB was observed by Evans blue method.
Results
concentration of VEGF protein was detected by enzyme-linked immunoabsorbert assay (ELISA). The results of each group were compared. Results The content of BRB leaked into retina was obvious lower in the control group than which in the other 3 diabetic groups（Plt;0.01）. There was no significant difference of the content of Evans blue between the two groups with different dosage of batroxobin (P＞0.05). The content of Evans blue was lower in the 2 diabetic groups with different dosage of batroxobin than which in the control group (Plt;0.05). The content of VEGF in retina was obviously lower in control group and 2 diabetic groups with different dosage of batroxobin than which in the diabetic group (Plt;0.01), and obviously lower in batroxobin (40 mg/kg) diabetic group than which in the control group (P＝0.01). The content of VEGF in control group and batroxobin (20 mg/kg) diabetic group (P＝0.06) didnprime;t differ much, which occurred similarly in batroxobin diabetic groups with different dosage (P＝0.78).
Conclusions
Batroxobin may alleviate the damage of function of BRB in diabetic rats and reduce the expression of VEGF, which suggests that batroxobin can protect the function of BRB to a certain extent.
(Chin J Ocul Fundus Dis, 2006, 22: 16-19)
